BioCryst Pharmaceuticals | BCRX - 应收帐款人



金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 2.05B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


应收帐款人 更改 日
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Chugai Pharma JPY 443.11B 89.26B 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
DBV Technologies USD 15.97M 279K 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 4.91B 182M 2025-12
GlaxoSmithKline GBP 7.76B 545M 2025-12
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Incyte USD 1.02B 128.52M 2025-12
Ionis Pharmaceuticals USD 66M 41.39M 2025-12
Karyopharm Therapeutics USD 31.78M 6.82M 2024-09
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novavax USD 106.45M 72.27M 2025-12
PTC Therapeutics USD 181.62M 21.45M 2025-12
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12